Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-enhanced Computed Tomography with Immunohistochemical Validation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 8

PMID 24098755

Citations 16

Authors

Clemens C Cyran

Philipp M Kazmierczak

Heidrun Hirner

Matthias Moser

Michael Ingrisch

Lukas Havla

Alexandra Michels

Ralf Eschbach

Bettina Schwarz

Maximilian F Reiser

Christiane J Bruns

Konstantin Nikolaou

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate dynamic contrast-enhanced computed tomography for monitoring the effects of regorafenib on experimental colon carcinomas in rats by quantitative assessments of tumor microcirculation parameters with immunohistochemical validation.

Materials And Methods: Colon carcinoma xenografts (HT-29) implanted subcutaneously in female athymic rats (n = 15) were imaged at baseline and after a one-week treatment with regorafenib by dynamic contrast-enhanced computed tomography (128-slice dual-source computed tomography). The therapy group (n = 7) received regorafenib daily (10 mg/kg bodyweight). Quantitative parameters of tumor microcirculation (plasma flow, mL/100 mL/min), endothelial permeability (PS, mL/100 mL/min), and tumor vascularity (plasma volume, %) were calculated using a 2-compartment uptake model. Dynamic contrast-enhanced computed tomography parameters were validated with immunohistochemical assessments of tumor microvascular density (CD-31), tumor cell apoptosis (TUNEL), and proliferation (Ki-67).

Results: Regorafenib suppressed tumor vascularity (15.7±5.3 to 5.5±3.5%; p<0.05) and tumor perfusion (12.8±2.3 to 8.8±2.9 mL/100 mL/min; p = 0.063). Significantly lower microvascular density was observed in the therapy group (CD-31; 48±10 vs. 113±25, p<0.05). In regorafenib-treated tumors, significantly more apoptotic cells (TUNEL; 11844±2927 vs. 5097±3463, p<0.05) were observed. Dynamic contrast-enhanced computed tomography tumor perfusion and tumor vascularity correlated significantly (p<0.05) with microvascular density (CD-31; r = 0.84 and 0.66) and inversely with apoptosis (TUNEL; r = -0.66 and -0.71).

Conclusions: Regorafenib significantly suppressed tumor vascularity (plasma volume) quantified by dynamic contrast-enhanced computed tomography in experimental colon carcinomas in rats with good-to-moderate correlations to an immunohistochemical gold standard. Tumor response biomarkers assessed by dynamic contrast-enhanced computed tomography may be a promising future approach to a more personalized and targeted cancer therapy.

Citing Articles

Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy.

Jiao J, Wu Y, Wu S, Jiang J Curr Treat Options Oncol. 2025; .

PMID: 40045029 DOI: 10.1007/s11864-025-01306-8.

Multikinase Treatment of Glioblastoma: Evaluating the Rationale for Regorafenib.

Munoz-Marmol A, Melendez B, Hernandez A, Sanz C, Domenech M, Arpi-Llucia O Cancers (Basel). 2025; 17(3).

PMID: 39941744 PMC: 11816343. DOI: 10.3390/cancers17030375.

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD.

Han K, Kang R, Jeon H, Lee H, Lee J, Park H Cells. 2020; 9(7).

PMID: 32660121 PMC: 7408082. DOI: 10.3390/cells9071655.

Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report.

Takeuchi N, Koike K, Yoshida S, Fujiwara M Oncol Lett. 2019; 18(6):6469-6474.

PMID: 31807169 PMC: 6876333. DOI: 10.3892/ol.2019.11043.

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.

Fondevila F, Mendez-Blanco C, Fernandez-Palanca P, Gonzalez-Gallego J, Mauriz J Exp Mol Med. 2019; 51(9):1-15.

PMID: 31551425 PMC: 6802659. DOI: 10.1038/s12276-019-0308-1.

References

Figlin R, Sternberg C, Wood C . Novel agents and approaches for advanced renal cell carcinoma. J Urol. 2012; 188(3):707-15. DOI: 10.1016/j.juro.2012.04.108. View

van der Meel R, Gallagher W, Oliveira S, OConnor A, Schiffelers R, Byrne A . Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov Today. 2009; 15(3-4):102-14. DOI: 10.1016/j.drudis.2009.12.003. View

Cyran C, von Einem J, Paprottka P, Schwarz B, Ingrisch M, Dietrich O . Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Invest Radiol. 2011; 47(1):49-57. DOI: 10.1097/RLI.0b013e3182300fe4. View

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

Miles K, Lee T, Goh V, Klotz E, Cuenod C, Bisdas S . Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol. 2012; 22(7):1430-41. DOI: 10.1007/s00330-012-2379-4. View

Koukourakis M, Mavanis I, Kouklakis G, Pitiakoudis M, Minopoulos G, Manolas C . Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol. 2007; 30(3):315-8. DOI: 10.1097/01.coc.0000258119.90805.ca. View

Kopetz S . "Right drug for the right patient": hurdles and the path forward in colorectal cancer. Am Soc Clin Oncol Educ Book. 2013; . DOI: 10.14694/EdBook_AM.2013.33.e115. View

Raatschen H, Fu Y, Brasch R, Pietsch H, Shames D, Yeh B . In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. Invest Radiol. 2009; 44(5):265-70. PMC: 4115801. DOI: 10.1097/RLI.0b013e31819f1b60. View

Jitawatanarat P, Wee W . Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol. 2013; 4(2):231-8. PMC: 3635194. DOI: 10.3978/j.issn.2078-6891.2013.008. View

10.

George M, Padhani A, Brown G, Tait D, Eccles S, Swift R . Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg. 2001; 88(12):1628-36. DOI: 10.1046/j.0007-1323.2001.01947.x. View

11.

Jost G, Pietsch H, Grenacher L . Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics. Invest Radiol. 2013; 48(10):715-21. DOI: 10.1097/RLI.0b013e318290cafb. View

12.

Shastry M, Miles K, Win T, Janes S, Endozo R, Meagher M . Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma. Mol Imaging. 2012; 11(5):353-60. PMC: 4210517. View

13.

Uller W, Wiggermann P, Gossmann H, Klebl F, Salzberger B, Stroszczynski C . Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): preliminary data. Clin Hemorheol Microcirc. 2012; 49(1-4):55-66. DOI: 10.3233/CH-2011-1457. View

14.

Cyran C, Paprottka P, Schwarz B, Sourbron S, Ingrisch M, Einem J . Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. AJR Am J Roentgenol. 2012; 198(2):384-91. DOI: 10.2214/AJR.11.6951. View

15.

Faria S, Ng C, Hess K, Phongkitkarun S, Szejnfeld J, Daliani D . CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007; 189(2):378-85. DOI: 10.2214/AJR.07.2164. View

16.

Zagouri F, Sergentanis T, Chrysikos D, Filipits M, Bartsch R . mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol. 2012; 127(3):662-72. DOI: 10.1016/j.ygyno.2012.08.040. View

17.

Bruns C, Harbison M, Davis D, Portera C, Tsan R, McConkey D . Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000; 6(5):1936-48. View

18.

Tai J, Tessier J, Ryan A, Hoffman L, Chen X, Lee T . Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia. 2010; 12(9):697-707. PMC: 2933690. DOI: 10.1593/neo.10292. View

19.

Fournier L, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J . Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology. 2010; 256(2):511-8. DOI: 10.1148/radiol.10091362. View

20.

Wilhelm S, Dumas J, Adnane L, Lynch M, Carter C, Schutz G . Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2010; 129(1):245-55. DOI: 10.1002/ijc.25864. View